Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...

Morgan Stanley upgraded shares of Vir Biotechnology (NASDAQ:VIR – Free Report) from an equal weight rating to an overweight rating in a report released on Thursday morning,Benzinga reports. They ...

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor ...

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...